Impact of Magnesium Stearate Presence and Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties.

drug solubility excipient variability magnesium stearate multivariate data analysis physicochemical properties

Journal

The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209

Informations de publication

Date de publication:
21 05 2020
Historique:
received: 27 09 2019
accepted: 20 03 2020
entrez: 23 5 2020
pubmed: 23 5 2020
medline: 10 6 2021
Statut: epublish

Résumé

Excipients are major components of oral solid dosage forms, and changes in their critical material attributes (excipient variability) and/or amount (excipient variation) in pharmaceutical formulations may present a challenge for product performance. Understanding the biopharmaceutical factors affecting excipient performance is recommended for the successful implementation of excipient variability on Quality by Design (QbD) approaches. The current study investigated the impact of magnesium stearate (MgSt) variability on the apparent solubility of drugs with a wide range of physicochemical properties (drug ionization, drug lipophilicity, drug aqueous solubility). Compendial and biorelevant media were used to assess the role of gastrointestinal (GI) conditions on the excipient effects on drug apparent solubility. The lipophilic nature of MgSt decreased the apparent solubility of most compounds. The reduction in drug apparent solubility was more pronounced for highly soluble and/or highly ionized drugs and in presence of more highly crystalline or smaller particle size MgSt. The use of multivariate data analysis revealed the critical physicochemical and biopharmaceutical factors and the complex nature of excipient variability on the reduction in drug apparent solubility. The construction of a roadmap combining drug, excipient and medium characteristics allowed the identification of the cases where the presence of excipient or excipient variability may present risks for oral drug performance.

Identifiants

pubmed: 32440810
doi: 10.1208/s12248-020-00449-w
pii: 10.1208/s12248-020-00449-w
pmc: PMC7242257
doi:

Substances chimiques

Stearic Acids 0
stearic acid 4ELV7Z65AP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

75

Références

J Pharm Pharmacol. 1985 Oct;37(10):681-5
pubmed: 2867134
J Pharm Pharmacol. 2010 Nov;62(11):1656-68
pubmed: 21039549
J Pharm Sci. 2006 Jan;95(1):4-14
pubmed: 16307451
Eur J Pharm Biopharm. 2017 Feb;111:1-15
pubmed: 27845182
J Pharm Sci. 2005 Oct;94(10):2121-31
pubmed: 16136567
Eur J Pharm Sci. 2014 Jun 16;57:99-151
pubmed: 24637348
Int J Pharm. 2007 Feb 22;331(1):84-92
pubmed: 17081708
Mol Pharm. 2009 Jan-Feb;6(1):40-7
pubmed: 19248231
Eur J Pharm Sci. 2016 Mar 31;85:94-105
pubmed: 26850682
J Pharm Sci. 2014 May;103(5):1466-77
pubmed: 24596131
Eur J Pharm Sci. 2014 Dec 18;65:89-97
pubmed: 25236823
Pharm Dev Technol. 2009;14(5):492-8
pubmed: 19241221
Drug Dev Ind Pharm. 2002 Oct;28(9):1147-53
pubmed: 12455473
J Pharm Sci. 2007 May;96(5):948-59
pubmed: 17455349
Drug Dev Ind Pharm. 2003 Feb;29(2):139-44
pubmed: 12648010
J Pharm Sci. 2010 Jun;99(6):2544-56
pubmed: 19960529
Eur J Pharm Sci. 2004 Jul;22(4):297-304
pubmed: 15196586
J Pharm Sci. 2017 May;106(5):1190-1196
pubmed: 28153596
Eur J Pharm Biopharm. 2010 May;75(1):1-15
pubmed: 20096779
Eur J Pharm Sci. 2015 Jan 25;67:65-75
pubmed: 25444845
Int J Pharm. 2000 Jul 20;202(1-2):47-62
pubmed: 10915926
Int J Pharm. 2015 May 15;485(1-2):229-34
pubmed: 25758158
Eur J Pharm Sci. 2016 May 25;87:88-99
pubmed: 26699228
AAPS PharmSciTech. 2015 Aug;16(4):771-86
pubmed: 25549792
AAPS J. 2010 Sep;12(3):397-406
pubmed: 20458565
Mol Pharm. 2012 Jul 2;9(7):1942-52
pubmed: 22651218
J Pharm Sci. 2014 Mar;103(3):920-6
pubmed: 24549733
Pharm Res. 2008 Jul;25(7):1663-76
pubmed: 18404251
Drug Deliv Transl Res. 2014 Jun;4(3):212-21
pubmed: 25786876
J Pharm Sci. 2017 Jan;106(1):338-347
pubmed: 27836109
Pharm Res. 2006 Oct;23(10):2454-68
pubmed: 16933092
AAPS PharmSciTech. 2013 Sep;14(3):1158-68
pubmed: 23897035
Int J Pharm. 2016 Sep 25;511(2):757-64
pubmed: 27444551
Drug Dev Ind Pharm. 2003 Feb;29(2):145-54
pubmed: 12648011
Drug Dev Ind Pharm. 2017 Feb;43(2):264-274
pubmed: 27645428
Pharm Dev Technol. 2017 Sep;22(6):715-723
pubmed: 26616157
Adv Drug Deliv Rev. 2007 Jul 30;59(7):568-90
pubmed: 17644216

Auteurs

P Zarmpi (P)

Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, UK.

T Flanagan (T)

Pharmaceutical Technology & Development, AstraZeneca, Macclesfield, UK.
UCB Pharma, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium.

E Meehan (E)

Pharmaceutical Technology & Development, AstraZeneca, Macclesfield, UK.

J Mann (J)

Pharmaceutical Technology & Development, AstraZeneca, Macclesfield, UK.

Nikoletta Fotaki (N)

Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, UK. n.fotaki@bath.ac.uk.

Articles similaires

Silicon Dioxide Water Hot Temperature Compressive Strength X-Ray Diffraction
Cobalt Azo Compounds Ferric Compounds Polyesters Photolysis
Inclusion Bodies Solubility Recombinant Proteins Detergents Protein Denaturation
Nanoparticles Needles Polylactic Acid-Polyglycolic Acid Copolymer Polyethylene Glycols Curcumin

Classifications MeSH